Trusted Resources: Education
Scientific literature and patient education texts
Immunoglobulin Light Chain Amyloid Aggregation
source: Chemical Communications
year: 2018
authors: Blancas-Mejia LM, Misra P, Dick CJ, Cooper SA, Redhage KR, Bergman MR, Jordan TL, Maar K, Ramirez-Alvarado M
summary/abstract:Light chain (AL) amyloidosis is a devastating, complex, and incurable protein misfolding disease. It is characterized by an abnormal proliferation of plasma cells (fully differentiated B cells) producing an excess of monoclonal immunoglobulin light chains that are secreted into circulation, where the light chains misfold, aggregate as amyloid fibrils in target organs, and cause organ dysfunction, organ failure, and death. In this article, we will review the factors that contribute to AL amyloidosis complexity, the findings by our laboratory from the last 16 years and the work from other laboratories on understanding the structural, kinetics, and thermodynamic contributions that drive immunoglobulin light chain-associated amyloidosis.
We will discuss the role of cofactors and the mechanism of cellular damage. Last, we will review our recent findings on the high resolution structure of AL amyloid fibrils. AL amyloidosis is the best example of protein sequence diversity in misfolding diseases, as each patient has a unique combination of germline donor sequences and multiple amino acid mutations in the protein that forms the amyloid fibril.
organization: Mayo Clinic, USADOI: 10.1039/c8cc04396e
read more
Related Content
-
Veterans and AL AmyloidosisAL Amyloidosis and Agent Orange Veteran...
-
MAGE Genes: Prognostic Indicators in AL Amyloidosis PatientsA high frequency of MAGE-CT (cancer te...
-
Efficacy of Chemotherapies and Stem Cell Transplantation for Systemic AL Amyloidosis: A Network Meta-AnalysisBackground/Aims: The present Bayesian n...
-
Immunoglobulin Light Chain Amyloidosis: 2016 Update on Diagnosis, Prognosis, and TreatmentDisease Overview: Immunoglobulin light ...
-
How Can I Avoid Fluid Balance Problems?Many patients with AL amyloidosis should...
-
Identification of Prognostic Markers in Transthyretin and AL Cardiac AmyloidosisBackground: The prognosis of amyloidosi...
-
Molecules That Curb Errant Proteins of AL Amyloidosis Point to New Type of TherapyScientists at Scripps Research have iden...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.